
The United States Food and Drug Administration approved ROCHE HOLDING AG-BR's oral treatment for advanced breast cancer on Monday. The approval covers combination therapy for patients carrying an ESR1 mutation.
The US Food and Drug Administration approved Roche oral treatment giredestrant for advanced breast cancer patients. The drug will be sold as Wilserdly and priced at twenty two thousand five hundred dollars per month.

The United States Food and Drug Administration approved ROCHE HOLDING AG-BR's oral treatment for advanced breast cancer on Monday. The approval covers combination therapy for patients carrying an ESR1 mutation.
Everything you use on the web — faster, and in your pocket.